Adaptimmune Therapeutics PLC
ADAPY$48M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaABINGDON, OXFORDSHIRE506 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ADAPY News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Letetresgene autoleucel (lete-cel, GSK3377794)
Neoplasms
Experimental: Letetresgene autoleucel
Neoplasms
NYESO-1c259 T cells
Ovarian Cancer
Letetresgene autoleucel
Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Letetresgene autoleucel (lete-cel, GSK3377794) | Phase 2 | Neoplasms | - | - |
Experimental: Letetresgene autoleucel | Phase 2 | Neoplasms | - | - |
NYESO-1c259 T cells | Phase 2 | Ovarian Cancer | - | - |
Letetresgene autoleucel | Phase 2 | Neoplasms | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply